These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23768168)

  • 21. PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway.
    Guan R; Kang Z; Li L; Yan X; Gao T
    PLoS One; 2024; 19(1):e0295813. PubMed ID: 38194422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
    Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
    Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
    Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
    Cheaib B; Auguste A; Leary A
    Chin J Cancer; 2015 Jan; 34(1):4-16. PubMed ID: 25556614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
    Tanaka H; Yoshida M; Tanimura H; Fujii T; Sakata K; Tachibana Y; Ohwada J; Ebiike H; Kuramoto S; Morita K; Yoshimura Y; Yamazaki T; Ishii N; Kondoh O; Aoki Y
    Clin Cancer Res; 2011 May; 17(10):3272-81. PubMed ID: 21558396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roles of TGFβ1 in the expression of phosphoinositide 3-kinase isoform genes and sensitivity and response of lung telocytes to PI3K inhibitors.
    Song D; Tang L; Wang L; Huang J; Zeng T; Fang H; Wang X
    Cell Biol Toxicol; 2020 Feb; 36(1):51-64. PubMed ID: 31522336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
    Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
    Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
    Levine DA; Bogomolniy F; Yee CJ; Lash A; Barakat RR; Borgen PI; Boyd J
    Clin Cancer Res; 2005 Apr; 11(8):2875-8. PubMed ID: 15837735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
    Chen J; Zhao KN; Li R; Shao R; Chen C
    Curr Med Chem; 2014; 21(26):3070-80. PubMed ID: 24735369
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Voutsadakis IA
    J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33435133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas.
    Madhukar G; Subbarao N
    J Biomol Struct Dyn; 2022 Jul; 40(10):4697-4712. PubMed ID: 33356909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
    Stamatkin C; Ratermann KL; Overley CW; Black EP
    Cancer Biol Ther; 2015; 16(9):1341-52. PubMed ID: 26176612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
    Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.
    Sewell A; Brown B; Biktasova A; Mills GB; Lu Y; Tyson DR; Issaeva N; Yarbrough WG
    Clin Cancer Res; 2014 May; 20(9):2300-11. PubMed ID: 24599934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the PI3K-AKT-mTOR pathway in penile cancer: evaluation of a therapeutically targetable pathway.
    Adimonye A; Stankiewicz E; Kudahetti S; Trevisan G; Tinwell B; Corbishley C; Lu YJ; Watkin N; Berney D
    Oncotarget; 2018 Mar; 9(22):16074-16086. PubMed ID: 29662627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic deregulation of the PIK3CA oncogene in oral cancer.
    Murugan AK; Munirajan AK; Tsuchida N
    Cancer Lett; 2013 Sep; 338(2):193-203. PubMed ID: 23597702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.